- Home
- FTHY vs ABEO Comparison
FTHY vs ABEO Comparison
Compare FTHY & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FTHY | ABEO |
|---|---|---|
| Founded | 2020 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 494.6M | 399.5M |
| IPO Year | 2020 | 2005 |
Fundamental Metrics
Financial Performance| Metric | FTHY | ABEO |
|---|---|---|
| Price | $13.45 | $6.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 95.7K | ★ 1.6M |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 10.93% | N/A |
| EPS Growth | N/A | ★ 165.16 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,998,000.00 |
| Revenue This Year | N/A | $1,024.31 |
| Revenue Next Year | N/A | $145.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $13.20 | $4.00 |
| 52 Week High | $14.84 | $7.65 |
Technical Indicators
Market Signals| Indicator | FTHY | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 45.63 | 43.52 |
| Support Level | $13.40 | $5.68 |
| Resistance Level | $13.71 | $7.51 |
| Average True Range (ATR) | 0.08 | 0.29 |
| MACD | -0.00 | -0.07 |
| Stochastic Oscillator | 62.15 | 18.21 |
Price Performance
Historical ComparisonAbout FTHY First Trust High Yield Opportunities 2027 Term Fund
FIRST TRUST HIGH YIELD OPPORTUNITIES 2027 TERM FUND is a diversified, closed-end management investment company. The investment objective of the fund is to provide current income. The fund invests a majority of its managed assets in high-yield debt securities of any maturity that are rated below investment grade at the time of purchase or unrated securities. Its investment portfolio comprises corporate bonds and notes, senior floating-rate loan interests, foreign corporate bonds and notes, money market funds, and other instruments across various industries.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.